Evidence suggests that tamoxifen—among the most extensively administered selective estrogen receptor modulators in hormone receptor–positive breast cancer patients—increases disease-free and overall survival rates (Lin and Winer, 2008). The gene discussed is NR4A1; the disease is breast cancer.